Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

2025 Foro de Terapias Dirigidas de Cáncer de Pulmón
AlexandraGBeneke
En este evento en directo, virtual, interactivo y dirigido por el Dr. Luis Raez en agosto de 2025, destacados oncólogos se reunieron para debatir las opciones de terapia dirigida en español para pacientes con cáncer de pulmón. El evento incluyó una sesión de preguntas y respuestas para la audiencia.
Author
Luis Raez, MD FACP FCCP

En este video, la Dra. Velázquez Mañana analiza las mutaciones del EGFR, los diferentes subtipos de cáncer de pulmón y cómo determinar cuál es el mejor tratamiento en general.

To watch the complete playlist, click here.

Special thanks to Genentech, BMS, Takeda, Johnson & Johnson, and Daiichi-Sankyo for their sponsorship of this program. 

Image
DS
Image
Janssen Logo

 

Image
BMS Logo

 

Image

 

Image
Genentech Logo

  

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

Hi app.92,  Welcome to Grace.  I'm sorry this is late getting to you. And more sorry your mum is going through this.  It's possible this isn't a pancoast tumor even though...

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

Recent Comments

JOIN THE CONVERSATION
Hi app.92,  Welcome to Grace…
By JanineT GRACE … on
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on